Biologically Focused Therapy of Treatment-Refractory MDS Patients

Not Recruiting

Trial ID: NCT05245032

Purpose

This non interventional study examines the feasibility of using patient specific therapeutic screening method, ex vivo to enhance current treatment recommendations in a clinically feasible time frame of 30 days.

Official Title

Biologically Focused Therapy of Treatment Refractory MDS Patients

Stanford Investigator(s)

Peter Greenberg
Peter Greenberg

Professor of Medicine (Hematology), Emeritus

Eligibility

Inclusion Criteria:

* Provide informed consent;
* Myelodysplastic syndrome as defined by WHO classification (see Appendix 2), or MDS/MPN with \>= 5% blasts in the bone marrow or peripheral blood, including chronic myelomonocytic leukemia (CMML) 1 and 2 by WHO classification
* Relapsed/refractory disease, defined as failed or are ineligible for hypomethylating agent therapy
* Cytogenetics reported

Exclusion Criteria:

* Hypoplastic MDS
* Patients without adequate marrow samples for ex vivo analysis

Not Recruiting

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
Jack Taw
650-723-2781

New Trial Alerts